PRODUCTS THERAPEUTIC CATEGORY AVAILABLE STATUS ON
Tech pack GMP EUWC US DMF EDMF/
CEP
MEXICO/
BRAZIL DMF
TDMF KDMF/
JDMF
PATENT
Azithromycin Dihydrate Macrolides WHO - A A A A
Agomelatine Form II Antidepressant WHO A A A A INDIA 851/MUM/2014
Aprepitant Form I And Form II Anti-Emetic WHO A A A A India 20116210 09118
Bisoprolol Hemifumarate 

(CEP NO..2013-342)

Anti Hypertensive WHO A A A
Bazedoxifene Acetate Form A & B Selective Estrogen Receptor Modulator INDIA 2018 2018 2018 2018 2018
Chloramphenicol Base & Palmitate Anti-Bacterial WHO
Cinacalcet Hcl Form I Calcimimetic INDIA - A A A A A PCT/India
IB2015 056205
Erythromycin Base -

CEP NO RO-CEP 2009-267

MACROLIDES WHO A A A
Erythromycin Ethyl Succinate

CEP-2017-281

WHO A A A A
Erythromycin Stearate WHO A A A A
Esmolol cardioselectivebeta1 receptor blocker WHO
Fluvoxamine Maleate Antidepressant WHO A A A A
Linagliptin Form A Anti diabetic INDIA A 2018 2018 2018 2018 2018
Mirabegron Form α Beta-3 adrenergic Receptor Activator INDIA A India 20162100 9117
Rivaroxaban Form I Anticoagulant INDIA A India PCT/IB20 16/053346
Treprostinil Vasodilator WHO A A A A



Under Development


PRODUCTS THERAPEUTIC CATEGORY DEVELOPMENT TIME LINE
Bimatoprost Prostaglandin 2018/2019
Clopidogrel Bisulphate Antiplatelet 2018/2019
Dabigatran Etexilate Mesylate Anticoagulant 2018/2019
Dapagliflozin Antidiabetic 2018/2019
Efavirenz Antiretroviral 2018/2019
Empagliflozin Antidiabetic 2018/2019
Latanoprost Prostaglandin 2018/2019
Lubiprostone Laxative 2018/2019
Luliconazole Antifungal 2018/2019
Sitagliptin Antidiabetic 2018/2019



Under Evaluation


PRODUCTS THERAPEUTIC CATEGORY
Betrixaban Anticoagulant
Brexpiprazole Antipsychotic
Beraprost Vasodilator and antiplatelet agent
Ertugliflozin Antidabetic
Hyaluronic Acid Other musculoskeletal agents
Limaprost Alfadex Vasodilator

The above products are offered as per BP/EP/USP/JP and FP and as per customers in-house specifications. Also available in Microfine the above products are intended to supplied solely as per usage reasonably relating to the testing and development of information, regulatory submission, strictly according to the section 107A of the Indian Patent Act, 1970.

  • Disclaimer:


    Mehta API has technical capabilities of manufacturing Linagliptin and Rivaroxaban and their Intermediates. However, these products will be offered only to the markets where product and process are not infringing. The quantities for the purpose of Research and Development of product for regulatory submission will be offered only to countries where such exemptions exists (Hatch Waxman Act/Bolar exemption) during the validity of the patent. While MAPL offers to work with the clients on status verification of patent, the ultimate responsibility vests with the buyer. Recipients of these APIs and intermediates are requested to make their independent evaluation and determination as to the patent status prior to the use of material and information in their respective jurisdiction. Products under patent offered only for exempted research, clinical and development purpose.